27 Oct, 2020 Alzheon Announces Dosing of First Patient in ALZ-801 Phase 2 Biomarker Study in APOE4 Carriers with Early Alzheimer’s Disease alzheon2024-08-26T10:55:47-04:00October 27th, 2020|Tags: PR| Read More
20 Aug, 2020 Alzheon Awarded $47 Million Grant from U.S. National Institute on Aging for Phase 3 Clinical Study of ALZ-801, an Oral Treatment for Alzheimer’s Disease alzheon2024-08-05T19:24:36-04:00August 20th, 2020|Tags: PR| Read More
